Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359211 | 0.81 | MAPT (0.40) | MAPTMAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3381395 | 0.81 | CA12 (0.41) | PPARASLC22A12SMN1; SMN2ALDH1A1 | |
| SCHEMBL27347338 | 0.81 | SLC22A12 (0.43) | PPARASLC22A12MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3150010 | 0.79 | SLC22A12 (0.50) | PPARASLC22A12ALDH1A1 | |
| SCHEMBL3284990 | 0.79 | ALDH1A1 (0.42) | MAPTSLC22A12MAOAALDH1A1NPSR1 | |
| SCHEMBL3841072 | 0.78 | SLC22A12 (0.51) | PPARASLC22A12MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31275147 | 0.77 | MAOA (0.46) | MAPTMAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2438988 | 0.77 | MAOA (0.46) | MAPTMAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10476068 | 0.77 | PPARA (0.49) | PPARAMAPTSLC22A12MEN1KMT2A | |
| SCHEMBL6779760 | 0.77 | UNG (0.46) | PPARAMAPTSLC22A12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | claimed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| EP-1856065-A1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006092507-A1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2006-09-08 | — | — | WO | disclosed |
| US-20040176445-A1 | Propionic acid derivatives | BAYER PHARMACEUTICALS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6750236-B2 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1328508-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| WO-2002028821-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | PPARA 1/4885MAPT 4388/4885SLC22A12 2850/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARA 2/4885MAPT 4503/4885SLC22A12 2969/4885 |
| US-20040176445-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | PPARA 2/4885MAPT 4503/4885SLC22A12 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.